Let’s not get excited about stem cells and GI bleeding, page-4

Just listened to the conference call, it sounds like there might actually be an avenue for progression to approval with current results but will be waiting until well into 2019 for meetings with the FDA to clear that up. If MSB announced that’s what the FDA were looking at beforehand then the market may have responded differently.

no difference in thrombosis rates between groups

As for the heart failure trial the jury is still out in my books, I’m slightly more hopeful but not by much. Not really any more info from the conference call.

And the way today panned our still rubs me the wrong way - the trading halt certainly should have continued until after this presentation. But I feel justified in not selling.

good luck everyone, hopefully tomorrow is a better day.